The potential of cannabidiol in theCOVID-19pandemic
The potential of cannabidiol in theCOVID-19pandemic
复制标题
DOI：
10.1111/bph.15157
复制
发表时间：
2020-07-16
影响因子：
7.3
通讯作者：
Sarnelli, Giovanni
中科院分区：
文献类型：
--
作者：
Esposito, Giuseppe;Pesce, Marcella;Sarnelli, Giovanni
确定对2019年新型冠状病毒病（COVID-19）有效的药物至关重要，等待针对SARS-CoV 2的疫苗。我们建议假设大麻二酚（CBD），一种非精神病植物大麻素，有可能限制疾病的严重程度和进展，原因有几个：- （a）高大麻二酚大麻提取物能够下调SARS-CoV 2的两种关键受体在几种人类上皮细胞模型中的表达，（B）大麻二酚发挥广泛的免疫调节和抗炎作用，并且它可以减轻导致急性肺损伤的不受控制的细胞因子产生，（c）是PPAR γ激动剂，它可以显示直接的抗病毒活性，和（d）PPAR γ激动剂是成纤维细胞/肌成纤维细胞活化的调节剂，并且可以抑制肺纤维化的发展，从而改善康复患者的肺功能。我们希望我们的假设得到临床前证据的证实，将激发进一步的靶向研究，以测试大麻二酚作为对抗COVID-19大流行的支持药物。
Identifying drugs effective in the new coronavirus disease 2019 (COVID-19) is crucial, pending a vaccine against SARS-CoV2. We suggest the hypothesis that cannabidiol (CBD), a non-psychotropic phytocannabinoid, has the potential to limit the severity and progression of the disease for several reasons:- (a) High-cannabidiolCannabis sativaextracts are able to down-regulate the expression of the two key receptors for SARS-CoV2 in several models of human epithelia, (b) cannabidiol exerts a wide range of immunomodulatory and anti-inflammatory effects and it can mitigate the uncontrolled cytokine production responsible for acute lung injury, (c) being a PPAR gamma agonist, it can display a direct antiviral activity and (d) PPAR gamma agonists are regulators of fibroblast/myofibroblast activation and can inhibit the development of pulmonary fibrosis, thus ameliorating lung function in recovered patients. We hope our hypothesis, corroborated by preclinical evidence, will inspire further targeted studies to test cannabidiol as a support drug against the COVID-19 pandemic.